What has changed over the year in the prevention of venous thromboembolic events in pregnant women and puerperas?
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.439
Abstract
An issue of venous thromboembolic events (VTEs) in pregnant women and puerperas in Russia as well as throughout the world remains relevant. Specialized events with expert’s participation could not be better to promote active discussion and constructive solution of complex problems, which refer to issues of VTEs prevention. Indeed, not disputable issues can be solved, but critical look and reasoned opinion leader presentations in the field undoubtedly improve our understanding and approaches to prevention of threatening complications in pregnant women and puerperas such as VTEs. In addition, actively discussed new data for dosing of low molecular weight heparins (LMWH) in pregnant women will allow to update current clinical guidelines, which would probably improve clinical outcomes of therapy.
About the Authors
V. O. Bitsadze
Sechenov University
Russian Federation
Russian Federation
Victoria O. Bitsadze – MD, Dr Sci Med, Professor of RAS, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health
Scopus Author ID: 6506003478.
Researcher ID: F-84092017
2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991
M. S. Zainulina
Snegirev Maternity Hospital № 6;
Pavlov First Saint Petersburg State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Marina S. Zainulina – MD, Dr Sci Med, Head Physician, Snegirev Maternity Hospital № 6, Saint Petersburg; Professor, Department of Obstetrics, Gynecology and Reproductive Medicine, Pavlov First Saint Petersburg State Medical University
Scopus Author ID: 37076359000.
Researcher ID: B-5746-2018.
5 Mayakovskogo Str., Saint Petersburg 192014;
6/8 Lev Tolstoy Str., Saint Petersburg 197022
J. Kh. Khizroeva
Sechenov University
Russian Federation
Russian Federation
Jamilya Kh. Khizroeva – MD, Dr Sci Med, Professor, Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health
Scopus Author ID: 57194547147.
Researcher ID: F-8384-2017
2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991
M. G. Nikolaeva
Altai State Medical University, Health Ministry of Russian Federation;
Altay Branch of National Medical Research Center for Hematology, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Mariya G. Nikolaeva – MD, Dr Sci Med, Professor, Department of Obstetrics and Gynecology with а Course of Professional Postgraduate Education, Altai State Medical University; Senior Researcher, Altai Branch of National Medical Research Center for Hematology
Scopus Author ID: 57191960907.
Researcher ID: AAI-6271-2020.
40 Lenin Avе., Barnaul 656038;
1 Lyapidevskogo Str., Barnaul 656045
A. D. Makatsariya
Sechenov University
Russian Federation
Russian Federation
Alexander D. Makatsariya – MD, Dr Sci Med, Academician of RAS, Professor, Head of the Department of Obstetrics, Gynecology and Perinatal Medicine, Filatov Clinical Institute of Children’s Health, Sechenov University; Vice-President of the Russian Society of Obstetricians and Gynecologists (RSOG); Honorary Doctor of the Russian Federation; Emeritus Professor of the University of Vienna
2 bldg. 4, Bolshaya Pirogovskaya Str., Moscow 119991
References
1. Surveillance of maternal deaths in the UK 2011-13 and lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009-13. MBRRACE-UK, 2015. 116 р. Available at: https://maternalmentalhealthalliance.org/wp-content/uploads/MBRRACE-UK-Maternal-Report-2015-3.pdf.
2. Health care in Russia. Statistical compendium. [Zdravoohranenie v Rossii. Statisticheskij sbornik]. Moscow: Federal'naya sluzhba gosudarstvennoj statistiki (Rosstat), 2019. 171 p. (In Russ.). Available at: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2019.pdf.
3. Gris J.-C., Aoun J., Rzaguliyeva L. et al. Risk assessment and management of venous thromboembolism in women during pregnancy and puerperium (SAVE): an international, cross-sectional study. TH Open. 2018;2(2):e116–e130. https://doi.org/10.1055/s-0038-1635573.
4. Anderson F.A., Spencer F.A. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):9–16. https://doi.org/10.1161/01.CIR.0000078469.07362.E6.
5. Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No. 37a. London: RCOG, 2015. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines.
6. Clinical guidelines – Venous complications during pregnancy and the postpartum period. Obstetric thromboembolism – 2022-2023-2024 (14.02.2022). [Klinicheskie rekomendacii – Venoznye oslozhneniya vo vremya beremennosti i poslerodovom periode. Akusherskaya tromboemboliya – 2022-2023-2024 (14.02.2022)]. Moscow: Health Ministry of Russian Federation, 2022. 66 p. (In Russ.). Available at: http://disuria.ru/_ld/11/1153_kr22O22MZ.pdf.
7. Federal Law of the Russian Federation of November 29, 2010 N 326-FZ – On Compulsory Medical Insurance in the Russian Federation – The latest version in force of February 24, 2021 – Edition N 35 – In force from February 24, 2021. [Federal'nyj zakon RF ot 29.11.2010 N 326-FZ – Ob obyazatel'nom medicinskom strahovanii v RF – Dejstvuyushchaya poslednyaya redakciya ot 24.02.2021 – Redakciya N 35 – V dejstvii s 24.02.2021]. 87 c. (In Russ.). Available at: http://disuria.ru/_ld/0/62_326FZ29112010.pdf.
8. Greer I.A., Nelson-Piercy С. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401–7. https://doi.org/10.1182/blood-2005-02-0626.
9. Simeone R., Giacomello R., Bruno G. et al. Thrombogenesis in thrombophilic pregnancy: evaluation of low-molecular-weight heparin prophylaxis. Acta Haematol. 2017;137(4):201–6. https://doi.org/10.1159/000467385.
10. ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. Obstet Gynecol. 2018;132(1):e18–e34. https://doi.org/10.1097/ AOG.0000000000002703.
11. Bates S.M., Middeldorp S., Rodger M. et al. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):92–128. https://doi.org/10.1007/s11239-015-1309-0.
12. Henriksson P., Westerlund E., Wallén H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013;346:e8632. https://doi.org/10.1136/bmj.e8632.
13. Hansen A.T., Kesmodel U.S., Juul S., Hvas A.M. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod. 2014;29(3):611–7. https://doi.org/10.1093/humrep/det458.
14. Olausson N., Discacciati A., Nyman A.I. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization with fresh respectively frozen-thawed embryo transfer: Nationwide cohort study. J Thromb Haemost. 2020;18(8):1965–73. https://doi.org/10.1111/jth.14840.
15. Arya R., Shehata H.A., Patel R.K. et al. Internal jugular vein thrombosis after assisted conception therapy. Br J Haematol. 2001;115(1):153–5. https://doi.org/10.1046/j.1365-2141.2001.03081.x.
16. Rova K., Henrik Passmark H., Lindqvist P.G. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012;97(1):95–100. https://doi.org/10.1016/j.fertnstert.2011.10.038.
17. Grandone E., Di Micco P.P., Villani M. et al.; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE Registry. Thromb Haemost. 2018;118(11):1962–8. https://doi.org/10.1055/s-0038-1673402.
18. van Lennep J.E.R., Meijer E., Klumper F.J.C.M et al. Low-molecularweight-heparin and pregnancy, when the dose does it: a nephrologist’s opinion: reply to a rebuttal. J Thromb Haemost. 2011;9(10):2129–30. https://doi.org/10.1111/j.1538-7836.2011.04441.x.
19. Bleker S.M., Buchmüller A., Chauleur C. et al. Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. Thromb Res. 2016;144:62–6. https://doi.org/10.1016/j.thromres.2016.06.001.
20. Bistervels I.M., Buchmüller A., Wiegers H.M.G. et al. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and postpartum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;400(10365):1777–87. https://doi.org/10.1016/S0140-6736(22)02128-6.
21. Shmakov R.G., Vavilova T.V., Nikolaeva M.G. et al. Brief algorithms for the diagnosis, prevention and treatment of venous thromboembolic complications during pregnancy. [Kratkie algoritmy diagnostiki, profilaktiki i lecheniya venoznyh tromboembolicheskih oslozhnenij vo vremya beremennosti]. Akusherstvo i ginekologiya. 2022;12 (prilozhenie):4–12. (In Russ.).
22. van der Wall S.J., Klok F.A., den Exter P.L. et al. Higher adherence to treatment with low-molecular-weight-heparin Nadroparin than Enoxaparin because of side effects in cancer-associated venous thromboembolism. Hemasphere. 2018;2(1):e19. https://doi.org/10.1097/HS9.0000000000000019.
23. Mismetti P., Laporte S., Darmon J.Y. et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88(7):913–30. https://doi.org/10.1046/j.0007-1323.2001.01800.x.
24. Snijder C.A., Cornette J.M.W., Hop W.C.J. et al. Thrombophylaxis and bleeding complications after cesarean section. Acta Obstet Gynecol Scand. 2012;91(5):560–56. https://doi.org/10.1111/j.1600-0412.2012.01351.x.
25. Bitsadze V.O., Slukhanchuk E.V., Khizroeva J.K. et al. Anticoagulant, antiinflammatory, antiviral and antitumor properties of heparins. [Antikoagulyantnye, protivovospalitel'nye, protivovirusnye i protivoopuholevye svojstva geparinov]. Obstetrics, Gynecology and Reproduction. 2021;15(3):295–312. (In Russ.). https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.216.
26. Antman E.M., Hand M., Armstrong P.W. et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;117:296–329. https://doi.org/10.1161/CIRCULATIONAHA.107.188209.
27. Hirsh J., Bauer K.A., Donati M.B. et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):141S–159S. https://doi.org/10.1378/chest.08-0689.
28. Fareed J., Walenga J.M., Hoppensteadt D. et al. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci. 1989;556:333–53. https://doi.org/10.1111/j.1749-6632.1989. tb22515.x.
29. Ofosu F.A. Differences in the safety profiles of two low-molecular-weight heparins. Thromb Haemost. 2008;99(6):989–90. https://doi.org/10.1160/TH08-05-0274.
30. Nenci G.G. Low molecular weight heparins: are they interchangeable? No. J Thromb Haemost. 2003;1:12–3.
31. van der Heijden J.F., Prins M.H., Büller H.R. Low molecular weight heparins: are they interchangeable? Haemostasis. 2000;30 Suppl 2:148– 57. https://doi.org/10.1159/000054183.
32. Kistler U., Kramers-de Quervain I., Munzinger U., Kucher N. Bleeding complications after systemic switch of routine prophylaxis for major orthopedic surgery. Thromb Haemost. 2008;99(6):1049–52. https://doi.org/10.1160/TH08-01-0019.
33. Maddineni J., Walenga J.M., Jeske W.P. et al. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Clin Appl Thromb Hemost. 2006;12(3):267–76. https://doi.org/10.1177/1076029606291434.
34. U.S. Identifies Tainted Heparin in 11 Countries. The New York Times. April 22, 2008. Available at: https://www.nytimes.com/2008/04/22/health/policy/22fda.html.
35. Stevenson J.G. Clinical Data and Regulatory Issues of Biosimilar Products. Am J Manag Care. 2016;21(16 Suppl):s320–s330.
36. Gray E., Rigsby P., Behr-Gross M.-E. Collaborative study to establish the low-molecular-mass heparin for assay – European Pharmacopoeia Biological Reference Preparation. Pharmeuropa Bio. 2004;2004(1):59–76.
37. Harenberg J., Kakkar A., Bergqvist D. et al.; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost. 2009;7(7):1222–5. https://doi.org/10.1111/j.1538-7836.2009.03349.x.
Review
For citations:
Bitsadze V.O., Zainulina M.S., Khizroeva J.Kh., Nikolaeva M.G., Makatsariya A.D. What has changed over the year in the prevention of venous thromboembolic events in pregnant women and puerperas? Obstetrics, Gynecology and Reproduction. 2023;17(4):533-545. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.439
Views:
981
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
